ABEONA THERAPEUTICS INC. Stock-Based Compensation
ABEONA THERAPEUTICS INC. (ABEO) reported Stock-Based Compensation of $6.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.37M, a 19.05% increase year-over-year.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.96M, a 9.48% increase year-over-year.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.56M, a 30.90% increase year-over-year.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.69M, a 49.06% increase year-over-year.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, noncash expense for fiscal 2025 was $10.78M, a 62.63% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, noncash expense for fiscal 2024 was $6.63M, a 39.01% increase from fiscal 2023.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, noncash expense for fiscal 2023 was $4.77M, a 56.28% increase from fiscal 2022.
- ABEONA THERAPEUTICS INC. share-based payment arrangement, noncash expense for fiscal 2022 was $3.05M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.33M 10-Q · filed 2026-08-13 | $8.88M derived: sum of 3 quarters · filed 2026-08-13 | $11.57M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $2.96M 10-Q · filed 2026-05-13 | $5.52M derived: sum of 2 quarters · filed 2026-05-13 | $8.21M derived: sum of 3 quarters · filed 2026-05-13 | $11.04M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.25M derived: sum of 2 quarters · filed 2026-03-17 | $8.08M derived: sum of 3 quarters · filed 2026-08-13 | $10.78M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $2.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.52M derived: sum of 2 quarters · filed 2026-08-13 | $8.22M 10-Q · filed 2025-11-12 | $10.18M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $2.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.53M 10-Q · filed 2026-08-13 | $7.49M derived: sum of 3 quarters · filed 2026-08-13 | $9.29M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $2.70M 10-Q · filed 2026-05-13 | $4.66M derived: sum of 2 quarters · filed 2026-05-13 | $6.46M derived: sum of 3 quarters · filed 2026-05-13 | $7.78M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.76M derived: sum of 2 quarters · filed 2026-03-17 | $5.08M derived: sum of 3 quarters · filed 2026-03-17 | $6.63M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.13M derived: sum of 2 quarters · filed 2025-11-12 | $4.67M 10-Q · filed 2025-11-12 | $6.19M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.87M 10-Q · filed 2025-08-14 | $4.38M derived: sum of 3 quarters · filed 2025-08-14 | $5.94M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $1.55M 10-Q · filed 2025-05-15 | $3.06M derived: sum of 2 quarters · filed 2025-05-15 | $4.62M derived: sum of 3 quarters · filed 2025-05-15 | $5.54M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.07M derived: sum of 2 quarters · filed 2025-03-20 | $4.00M derived: sum of 3 quarters · filed 2025-03-20 | $4.77M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.48M derived: sum of 2 quarters · filed 2024-11-14 | $3.25M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $927.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.70M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $770.00K 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | $3.05M 10-K · filed 2024-03-18 | ||||
| 2016-03-31 | $1.59M 10-Q · filed 2016-05-16 | $3.11M derived: sum of 2 quarters · filed 2016-05-16 | $4.83M derived: sum of 3 quarters · filed 2016-05-16 | $5.74M derived: sum of 4 quarters · filed 2016-05-16 | |
| 2015-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $3.24M derived: sum of 2 quarters · filed 2016-03-30 | $4.14M derived: sum of 3 quarters · filed 2016-03-30 | $4.37M 10-K · filed 2016-03-30 | |
| 2015-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | $2.63M derived: sum of 2 quarters · filed 2015-11-16 | $2.85M 10-Q · filed 2015-11-16 | $3.00M derived: sum of 4 quarters · filed 2016-05-16 | |
| 2015-06-30 | $904.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $1.13M 10-Q · filed 2015-08-14 | $1.27M derived: sum of 3 quarters · filed 2016-05-16 | $1.45M derived: sum of 4 quarters · filed 2016-05-16 | |
| 2015-03-31 | $224.00K 10-Q · filed 2016-05-16 | $370.00K derived: sum of 2 quarters · filed 2016-05-16 | $542.00K derived: sum of 3 quarters · filed 2016-05-16 | $734.00K derived: sum of 4 quarters · filed 2016-05-16 | |
| 2014-12-31 | $146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $318.00K derived: sum of 2 quarters · filed 2016-03-30 | $510.00K derived: sum of 3 quarters · filed 2016-03-30 | $1.30M 10-K · filed 2016-03-30 | |
| 2014-09-30 | $172.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | $364.00K derived: sum of 2 quarters · filed 2015-11-16 | $1.16M 10-Q · filed 2015-11-16 | $1.24M derived: sum of 4 quarters · filed 2015-11-16 | |
| 2014-06-30 | $192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $987.00K 10-Q · filed 2015-08-14 | $1.07M derived: sum of 3 quarters · filed 2015-08-14 | $1.10M derived: sum of 4 quarters · filed 2015-08-14 | |
| 2014-03-31 | $795.00K 10-Q · filed 2015-05-14 | $64.00K 10-Q · filed 2014-05-12 | $880.00K derived: sum of 2 quarters · filed 2015-05-14 | $906.00K derived: sum of 3 quarters · filed 2015-05-14 | $1.16M derived: sum of 4 quarters · filed 2015-05-14 |
| 2013-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $111.00K derived: sum of 2 quarters · filed 2015-03-31 | $362.00K derived: sum of 3 quarters · filed 2015-03-31 | $439.00K 10-K · filed 2015-03-31 | |
| 2013-09-30 | $26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $277.00K derived: sum of 2 quarters · filed 2014-11-14 | $354.00K 10-Q · filed 2014-11-14 | $437.00K derived: sum of 4 quarters · filed 2014-11-14 | |
| 2013-06-30 | $251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $328.00K 10-Q · filed 2014-08-14 | $411.00K derived: sum of 3 quarters · filed 2014-08-14 | $496.00K derived: sum of 4 quarters · filed 2014-08-14 | |
| 2013-03-31 | $77.00K 10-Q · filed 2014-05-12 | $160.00K derived: sum of 2 quarters · filed 2014-05-12 | $245.00K derived: sum of 3 quarters · filed 2014-05-12 | $353.00K derived: sum of 4 quarters · filed 2014-05-12 | |
| 2012-12-31 | $83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | $168.00K derived: sum of 2 quarters · filed 2014-03-26 | $276.00K derived: sum of 3 quarters · filed 2014-03-26 | $390.00K 10-K · filed 2014-03-26 | |
| 2012-09-30 | $85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $193.00K derived: sum of 2 quarters · filed 2013-11-14 | $307.00K 10-Q · filed 2013-11-14 | $606.00K derived: sum of 4 quarters · filed 2013-11-14 | |
| 2012-06-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $222.00K 10-Q · filed 2013-08-14 | $521.00K derived: sum of 3 quarters · filed 2013-08-14 | $865.00K derived: sum of 4 quarters · filed 2013-08-14 | |
| 2012-03-31 | $114.00K 10-Q · filed 2013-05-15 | $413.00K derived: sum of 2 quarters · filed 2013-05-15 | $757.00K derived: sum of 3 quarters · filed 2013-05-15 | $999.00K derived: sum of 4 quarters · filed 2013-05-15 | |
| 2011-12-31 | $299.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-20 | $643.00K derived: sum of 2 quarters · filed 2013-03-20 | $885.00K derived: sum of 3 quarters · filed 2013-03-20 | $1.07M 10-K · filed 2013-03-20 | |
| 2011-09-30 | $344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $586.00K derived: sum of 2 quarters · filed 2012-11-14 | $767.00K 10-Q · filed 2012-11-14 | $944.00K derived: sum of 4 quarters · filed 2012-11-14 | |
| 2011-06-30 | $242.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $423.00K 10-Q · filed 2012-08-14 | $600.00K derived: sum of 3 quarters · filed 2012-08-14 | $884.00K derived: sum of 4 quarters · filed 2012-08-14 | |
| 2011-03-31 | $181.00K 10-Q · filed 2012-05-15 | $358.00K derived: sum of 2 quarters · filed 2012-05-15 | $642.00K derived: sum of 3 quarters · filed 2012-05-15 | ||
| 2010-12-31 | $177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-23 | $461.00K derived: sum of 2 quarters · filed 2012-03-23 | $1.01M 10-K · filed 2012-03-23 | ||
| 2010-09-30 | $284.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $838.00K 10-Q · filed 2011-11-14 | |||
| 2010-06-30 | $554.00K 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |